NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.01 +0.01 (+0.01%) GOLD FUTURES
2,312.50 +1.50 (+0.06%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
46,889.95 +1,247.71 (+2.73%)
Ardelyx, Inc. (ARDX)
After hours:
| Previous close | 6.61 |
| Open | 6.69 |
| Bid | 6.76 x 1600 |
| Ask | 6.79 x 2600 |
| Day's range | 6.53 - 6.84 |
| 52-week range | 3.16 - 10.13 |
| Volume | |
| Avg. volume | 5,555,186 |
| Market cap | 1.589B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.55 |
GlobeNewswireArdelyx Reports First Quarter 2024 Financial Results and Provides Business Update
Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately $203 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-cl
- GlobeNewswire
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting XPHOZAH® (tenapanor) will be presented at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings, to be held May 14-18, 2024, in Long Beach, California. XPHOZAH, the first and only phosphate
ZacksRigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
